Hepregen is a life-science company developing bioengineered solutions for drug development, including a platform for advanced toxicity screening and drug discovery. The Massachusetts Institute of Technology spin-out is initially focused on the commercialization of a unique microliver platform. Combining tissue engineering and microfabrication to create optimized, precise and organized microlivers that are highly functional and stable, the platform has the potential to improve clinical predictivity of the liver’s response to drugs along the path of development. Mort Collins is chairman of the Board of Directors. (See deal announcement.)
Company Web Site
www.hepregen.com
|
